RecruitingOverweight or ObesityAtrial Fibrillation
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Eligible age
18–75 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Sponsor: University of Chicago
You may qualify if…
- ✓ 1. Age 18-75 years
- ✓ 2. BMI greater than or equal to 30 kg/m2
- ✓ 3. Paroxysmal AF or persistent AF, in whom catheter ablation (CA) for AF is expected within 1 year (A group) or in whom catheter ablation is NOT expected within 1 year (M group)
- ✓ 4. Ability to provide informed consent before any trial-related activities.
- ✓ 5. Patients with type 2 diabetes mellitus (T2DM) will be included:
- ✓ 1. If HbA1c (glycated hemoglobin) is less than or equal to 10 %
- ✓ 2. If the subject is taking basal insulin only or oral hypoglycemic agents or a combination of those.
- ✓ 3. Patients on SGLT2-inhibitors and TZDs (Thiazolidinedione) will be included if they have been on a stable dose of these medications for at least 6 months
You may not qualify if…
- ✕ 1. Current use of GLP-1 RA (glucagon-like peptide receptor agonists) or DPP4 (Dipeptidyl peptidase-4)-inhibitors or use within the last 90 days prior to screening
- ✕ 2. Current antiobesity medication use or use within the last 90 days prior to screening
- ✕ 3. A self-reported change in body weight of \> 5 kg (11 lb.) within 30 days before screening
- ✕ 4. History of bariatric surgery
- ✕ 5. History of type I diabetes mellitus
- ✕ 6. Current use of prandial insulin
- ✕ 7. Hospitalization for unstable angina, or TIA (Transient ischemic attack) \< 30 days prior to screening
- ✕ 8. Pulmonary embolism \< 90 days before screening
Where it's recruiting
Source: ClinicalTrials.gov · NCT06499857 · last updated 2025-11-14